Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in bronchodilator therapy

H S Nelson1

  • 1National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.

Current Opinion in Pulmonary Medicine
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure.

Allergy·2014
Same author

Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report.

Allergy·2013
Same author

Levosalbutamol: a viewpoint by Harold S. Nelson.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate.

International journal of clinical practice·2002
Same author

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2001
Same author

Onset and persistence of childhood asthma: predictors from infancy.

Pediatrics·2001
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Bronchodilators like salmeterol and theophylline offer effective asthma management. Salmeterol improved quality of life, while theophylline reduced inflammation, showing benefits beyond symptom control.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Bronchodilators are key in asthma therapy.
  • Concerns exist regarding specific bronchodilator safety and efficacy.
  • Asthma mortality risk factors require further investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of various bronchodilators in asthma management.
  • To compare long-acting beta-agonists (LABAs) and theophylline with other asthma treatments.
  • To assess the impact of bronchodilators on asthma control, quality of life, and inflammatory markers.

Main Methods:

  • Analysis of asthma mortality data.
  • Comparative studies of salmeterol versus oral beta-adrenergic agonists and theophylline.

Related Experiment Videos

  • Evaluation of salmeterol combined with inhaled corticosteroids (ICS) versus higher-dose ICS alone.
  • Assessment of regular salmeterol versus albuterol on quality of life.
  • Investigation of theophylline's effects on asthma control and inflammatory markers.

    • Main Results:

    • Fenoterol use, not beta-adrenergic bronchodilators as a class, was linked to asthma mortality risk.
    • Salmeterol demonstrated superior asthma symptom control and fewer adverse effects than oral beta-agonists and theophylline.
    • Combination therapy with low-dose ICS and salmeterol outperformed moderate-dose ICS alone.
    • Regular salmeterol use significantly improved patient quality of life, unlike albuterol.
    • Theophylline improved asthma control and reduced inflammatory markers (lymphocytes, eosinophils, cytokines) at low blood levels.

    Conclusions:

    • Salmeterol offers significant benefits in asthma symptom control, quality of life, and is a valuable addition to inhaled corticosteroid therapy.
    • Theophylline, even at low doses, effectively controls asthma symptoms and reduces airway inflammation.
    • Asthma mortality risk appears associated with specific agents like fenoterol rather than bronchodilators broadly.
    • These findings support the judicious use of specific bronchodilators in comprehensive asthma treatment plans.